* Eledon Pharmaceuticals Inc ELDN.OQ ELDN.O is expected
to show no change in quarterly revenue when it reports
results on November 7 (estimated) for the period ending
September 30 2024
*
* LSEG's mean analyst estimate for Eledon Pharmaceuticals
Inc is
for a loss of 31 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Eledon
Pharmaceuticals Inc is $10.00, above its last closing price
of $4.99.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.29 -0.30 -1.06 Missed -249.4
Mar. 31 2024 -0.36 -0.37 -0.34 Beat 7
Dec. 31 2023 -0.39 -0.29 Beat 26
Sep. 30 2023 -0.50 -0.46 -0.35 Beat 24
Jun. -0.46 -0.46 -0.40 Beat 12.8
30 2023
Jan. 1 0001 -0.58 -0.60 -0.75 Missed -25.2
Jan. 1 0001 -0.78 -0.69 1.6
Sep. 30 2022 -0.68 -0.68 -0.73 Missed -7.4
This summary was machine generated November 6 at 13:50 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)